Gloria A. Meshberg, NP

Gloria Meshberg practices at NewYork-Presbyterian/Weill Cornell Medical Center in New York, New York, part of NewYork-Presbyterian Hospital.

Gloria Meshberg's NPI, 1437629938, was assigned on November 28, 2018. Gloria Meshberg holds New York license 343745.

Gloria Meshberg's primary practice is NewYork-Presbyterian/Weill Cornell Medical Center, at 525 East 68th Street, New York, NY 10065 in New York County. The practice phone is (212) 746-5454.

Gloria Meshberg's primary practice is NewYork-Presbyterian/Weill Cornell Medical Center in New York, New York, part of NewYork-Presbyterian Hospital. The medical group on file is Montefiore Einstein Faculty Practice Group. Dmand AI also links Gloria Meshberg to 2 more clinical labs, 1 group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Gloria Meshberg practices, 4 sites in all. Vendor and product names are available with a free account.

Family is Gloria Meshberg's primary specialty in the NPI Registry, under taxonomy code 363LF0000X. Gloria Meshberg is licensed in New York.

Dmand AI lists chronic diabetes and chronic kidney disease among the conditions Gloria Meshberg treats.

CMS data shows 67 Medicare services from Gloria Meshberg across 3 procedure codes in 2024, for 28 Medicare patients. Medicare paid $4,320 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 28 Medicare patients who saw Gloria Meshberg in 2024. The largest group is 65 to 74, with 16 patients. 75% of them have high blood pressure, and 75% have high cholesterol. Their average risk score is 3.42, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Gloria Meshberg's median patient age at 61, with 47% women.

In 2024, Gloria Meshberg wrote 529 Medicare Part D claims for 86 patients. 76% of them were for generic drugs. CMS names the drug for 336 of them, across 16 drugs with 11 or more claims each, at $446,043 in total drug cost.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Gloria Meshberg for performance year 2024, reported through an alternative payment model (APM). Gloria Meshberg accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Gloria Meshberg as offering telehealth.

CMS Open Payments shows 29 general payments to Gloria Meshberg from 7 drug and device companies from 2024 to 2025. Food and beverage make up the largest share, 100% of the total. Gilead Sciences, Inc. paid the most, $285.